Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - SAFECODE DRUG TECHNOLOGIES CORP. | v338598_ex31-2.htm |
| EXCEL - IDEA: XBRL DOCUMENT - SAFECODE DRUG TECHNOLOGIES CORP. | Financial_Report.xls |
| 10-K - FORM 10-K - SAFECODE DRUG TECHNOLOGIES CORP. | v338598_10k.htm |
| EX-32.2 - EXHIBIT 32.2 - SAFECODE DRUG TECHNOLOGIES CORP. | v338598_ex32-2.htm |
| EX-31.1 - EXHIBIT 31.1 - SAFECODE DRUG TECHNOLOGIES CORP. | v338598_ex31-1.htm |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Joel Klopfer the Chief Executive Officer, and Director of SAFECODE DRUG TECHNOLOGIES CORP , certifies, under the standards set forth and solely for the purposes of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge, the Annual Report on Form 10-K of the Registrant for the fiscal year ended December 31, 2012, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in that Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
| Date: March 25, 2013 | SafeCode Drug Technologies Corp | ||
| By: | /s/ Joel Klopfer | ||
|
Name: Title: Chief Executive Officer, and Director | |||
A signed original of this written statement required by Section 906 has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.